Literature DB >> 11599591

A validated liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry method for quantitation of cocaine and benzoylecgonine in human plasma.

S N Lin1, D E Moody, G E Bigelow, R L Foltz.   

Abstract

In order to support studies on various medication protocols for the treatment of cocaine abuse, an accurate, precise, and sensitive (2.5 to 750 ng/mL) liquid chromatography-tandem mass spectrometry assay was developed to determine cocaine and benzoylecgonine in human plasma. Cocaine-d3 and benzoylecgonine-d3 were added as internal standards and samples were subjected to solid-phase extraction. Cocaine recovery was 94.4% and benzoylecgonine was 80.3% at 2.5 ng/mL. The selected reaction monitoring of parent ions at m/z 304 and 290 resulted in strong fragments at m/z 182 and 168 for cocaine and benzoylecgonine, respectively. The method was fully validated. The mean measured concentration at the 2.5 ng/mL, the lower limit of quantitation, was within 10.8% of the target and the precision determined at the low (5 ng/mL), medium (50 ng/mL), and high (650 ng/mL) quality controls ranged from 0.9 to 6.2 %CV. Cocaine and benzoylecgonine concentrations in plasma treated with 1% NaF showed changes of less than 10% when maintained at room temperature for up to 7 h and no significant changes when subjected to three freeze-thaw cycles. The concentrations of cocaine and benzoylecgonine remained stable in plasma samples stored at -20 degrees C for up to 11 months. Methanolic stock solutions of both analytes are stable, staying within 2% of the freshly prepared stock solutions, when stored at -20 degrees C for up to 235 days. Both extracted analytes reconstituted in methanolic solutions are stable for up to seven days whether stored at -20 degrees C or at room temperature on the autosampler. The method is rugged, rapid, and robust and has been applied to the batch analysis of more than 700 samples during pharmacokinetic profiling to assess potential interactions between intravenous (i.v.) cocaine challenge and treament medications. Results from three of these subjects receiving 40 mg (i.v.) cocaine demonstrate the utility of the method.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11599591     DOI: 10.1093/jat/25.7.497

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  22 in total

1.  Cocaine cardiovascular effects and pharmacokinetics after treatment with the acetylcholinesterase inhibitor donepezil.

Authors:  Kenneth Grasing; Deepan Mathur; Cherilyn DeSouza; Thomas F Newton; David E Moody; Marc Sturgill
Journal:  Am J Addict       Date:  2016-07-08

2.  Plasma cocaine levels, metabolites, and locomotor activity after subcutaneous cocaine injection are stable across the postpartum period in rats.

Authors:  Michael P Wansaw; Shen-Nan Lin; Joan I Morrell
Journal:  Pharmacol Biochem Behav       Date:  2005-08-22       Impact factor: 3.533

3.  Modafinil influences the pharmacokinetics of intravenous cocaine in healthy cocaine-dependent volunteers.

Authors:  Jennifer L Donovan; C Lindsay DeVane; Robert J Malcolm; Jurij Mojsiak; C Nora Chiang; Ahmed Elkashef; Robin M Taylor
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

4.  Screening of cocaine and its metabolites in human urine samples by direct analysis in real-time source coupled to time-of-flight mass spectrometry after online preconcentration utilizing microextraction by packed sorbent.

Authors:  Eshwar Jagerdeo; Mohamed Abdel-Rehim
Journal:  J Am Soc Mass Spectrom       Date:  2009-03-04       Impact factor: 3.109

5.  Application of programmable bio-nano-chip system for the quantitative detection of drugs of abuse in oral fluids.

Authors:  Nicolaos Christodoulides; Richard De La Garza; Glennon W Simmons; Michael P McRae; Jorge Wong; Thomas F Newton; Regina Smith; James J Mahoney; Justin Hohenstein; Sobeyda Gomez; Pierre N Floriano; Humberto Talavera; Daniel J Sloan; David E Moody; David M Andrenyak; Thomas R Kosten; Ahmed Haque; John T McDevitt
Journal:  Drug Alcohol Depend       Date:  2015-05-22       Impact factor: 4.492

6.  Characterization of a recombinant humanized anti-cocaine monoclonal antibody produced from multiple clones for the selection of a master cell bank candidate.

Authors:  Hanna N Wetzel; Rose P Webster; Fatima O Saeed; Terence L Kirley; William J Ball; Andrew B Norman
Journal:  Biochem Biophys Res Commun       Date:  2017-04-23       Impact factor: 3.575

7.  Role of individual and developmental differences in voluntary cocaine intake in rats.

Authors:  Nicole L Schramm-Sapyta; Marty C Cauley; Dalene K Stangl; Susan Glowacz; K Amy Stepp; Edward D Levin; Cynthia M Kuhn
Journal:  Psychopharmacology (Berl)       Date:  2011-02-24       Impact factor: 4.530

8.  Diffusion tensor imaging of cocaine-treated rodents.

Authors:  Ponnada A Narayana; Pallavi Ahobila-Vajjula; Jaivijay Ramu; Juan Herrera; Joel L Steinberg; F Gerard Moeller
Journal:  Psychiatry Res       Date:  2009-02-12       Impact factor: 3.222

9.  Adolescents are more vulnerable to cocaine addiction: behavioral and electrophysiological evidence.

Authors:  Wai Chong Wong; Kerstin A Ford; Nicole E Pagels; James E McCutcheon; Michela Marinelli
Journal:  J Neurosci       Date:  2013-03-13       Impact factor: 6.167

10.  Simultaneous determination of L-tetrahydropalmatine and cocaine in human plasma by simple UPLC-FLD method: application in clinical studies.

Authors:  Mingming Yu; Hazem E Hassan; Ahmed Ibrahim; Kenneth S Bauer; Deanna L Kelly; Jia Bei Wang
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2014-06-20       Impact factor: 3.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.